| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/J.AJKD.2010.10.049 |
| P8608 | Fatcat ID | release_v6qiqps5lrcurpywxt6ybwpc4a |
| P932 | PMC publication ID | 3062650 |
| P698 | PubMed publication ID | 21194817 |
| P5875 | ResearchGate publication ID | 49717910 |
| P50 | author | Kristian Thorlund | Q30089886 |
| Annette Bruchfeld | Q56981081 | ||
| Loïc Guillevin | Q88410079 | ||
| P2093 | author name string | Michael Walsh | |
| Peter A Merkel | |||
| Marion Haubitz | |||
| Wladimir Szpirt | |||
| David Jayne | |||
| Chen Au Peh | |||
| Fausta Catapano | |||
| Charles Pusey | |||
| P2860 | cites work | Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice | Q24553315 |
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies | Q28298876 | ||
| Nomenclature of systemic vasculitides. Proposal of an international consensus conference | Q29616304 | ||
| Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review | Q34005586 | ||
| Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study | Q35094863 | ||
| Rituximab versus cyclophosphamide for ANCA-associated vasculitis | Q35109118 | ||
| The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis | Q37247173 | ||
| Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis | Q40658134 | ||
| A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies | Q42163521 | ||
| Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis | Q42963758 | ||
| Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study. | Q43419315 | ||
| Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis | Q43471039 | ||
| Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? | Q43707230 | ||
| Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis | Q43843951 | ||
| Pulmonary renal syndrome: a 4-year, single-center experience | Q43843952 | ||
| Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement | Q44358548 | ||
| Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis | Q44419035 | ||
| Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. | Q46006712 | ||
| Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative St | Q46970196 | ||
| ANCA are pathogenic--oh yes they are! | Q55035940 | ||
| A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group | Q68037761 | ||
| The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels | Q68872851 | ||
| Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study | Q70215850 | ||
| Effect of intensive plasma exchange (PE) in rapidly progressive crescentic glomerulonephritis (RPCGN) | Q71102573 | ||
| Respiratory failure in ANCA-associated vasculitis | Q71234059 | ||
| Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospect | Q71561244 | ||
| Aggressive treatment with pulse methylprednisolone or plasma exchange is justified in rapidly progressive glomerulonephritis | Q71807906 | ||
| Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis | Q80507400 | ||
| Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial | Q84473965 | ||
| P433 | issue | 4 | |
| P921 | main subject | glomerulonephritis | Q605006 |
| meta-analysis | Q815382 | ||
| rapidly progressive glomerulonephritis | Q1509367 | ||
| P304 | page(s) | 566-574 | |
| P577 | publication date | 2010-12-30 | |
| P1433 | published in | American Journal of Kidney Diseases | Q4744250 |
| P1476 | title | Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis | |
| P478 | volume | 57 |
| Q92504772 | A Case of Diffuse Alveolar Hemorrhage Associated with High-Titer of MPO-ANCA Demonstrating Cytoplasmic Staining Pattern |
| Q35678050 | ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study |
| Q38034940 | Advances in therapy for ANCA-associated vasculitis |
| Q38082991 | Antineutrophil cytoplasm antibody-associated vasculitis: recent developments |
| Q55340553 | Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy. |
| Q38082735 | Apheresis therapy in children: an overview of key technical aspects and a review of experience in pediatric renal disease |
| Q35836369 | Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service |
| Q38543360 | Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients? |
| Q85410786 | Crescentic glomerulonephritis and membranous nephropathy: a rare coexistence |
| Q51561480 | Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. |
| Q40684657 | EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. |
| Q37640836 | Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis |
| Q44119588 | Glomerular disease: ANCA-associated GN--to PLEX or not to PLEX? |
| Q30276550 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue |
| Q45034297 | Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. |
| Q64058128 | Incidentally Diagnosed Alport Syndrome in a Patient with Drug-Induced Vasculitis |
| Q24187038 | Interventions for renal vasculitis in adults |
| Q35672892 | Linking classification and therapeutic management of vasculitides |
| Q86651438 | Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear |
| Q37093451 | Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study |
| Q41914211 | Microscopic polyangiitis: Atypical presentation with extensive small bowel necrosis, diffuse alveolar hemorrhage, and renal failure |
| Q94673520 | Narrative Review of Hypercoagulability in Small-Vessel Vasculitis |
| Q38135271 | New-generation therapy for ANCA-associated vasculitis |
| Q90590669 | PEXIVAS challenges current ANCA-associated vasculitis therapy |
| Q99608017 | PEXIVAS: The End of Plasmapheresis for ANCA-Associated Vasculitis? |
| Q39072021 | Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. |
| Q38946711 | Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement. |
| Q36199241 | Pauci-Immune Necrotizing and Crescentic Glomerulonephritis with Membranous Lupus Nephritis, Fifteen Years after Initial Diagnosis of Secondary Membranous Nephropathy |
| Q89694411 | Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis |
| Q36715376 | Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial |
| Q38377281 | Plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis--a 25-year perspective |
| Q27027106 | Plasmapheresis in immunologic renal disease |
| Q41099072 | Plasmapheresis therapy in ANCA-associated vasculitides: A single-center retrospective analysis of renal outcome and mortality |
| Q21195258 | Progress in treatment of ANCA-associated vasculitis |
| Q26751357 | Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q26747046 | Recent advances in understanding and treating vasculitis |
| Q54536081 | Renal outcome and risk factors for end-stage renal disease in pediatric rapidly progressive glomerulonephritis. |
| Q38489783 | Role of therapeutic plasmapheresis in ANCA-associated vasculitis. |
| Q50076914 | S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis |
| Q87954665 | The treatment of ANCA-associated rapidly-progressive glomerulonephritis and Goodpasture syndrome with therapeutic apheresis |
| Q64106271 | Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases |
| Q64260727 | Therapeutic Plasma Exchange in Renal Disorders |
| Q91991945 | Therapeutic plasma exchange - A brief review of indications, urgency, schedule, and technical aspects |
| Q30454997 | Therapeutic plasma exchange for renal-related conditions in the elderly: ten years experience in one center |
| Q91566737 | Therapeutic plasma exchange in nephrology. Where it applies? |
| Q38965278 | Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective. |
| Q38159916 | Treatment of ANCA-associated vasculitis. |
| Q30486655 | Treatment of renal manifestations of ANCA-associated vasculitis |
| Q41192540 | Treatment strategies for ANCA-associated vasculitides |
| Q42563782 | Understanding the role of rituximab in ANCA GN: regressing toward the mean |
| Q83308499 | Update on the treatment of granulomatosis with polyangiitis (Wegener's) |
| Q28069897 | Updates in ANCA-associated vasculitis |
| Q39215583 | Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the US. |
| Q28259540 | What is new in the management of rapidly progressive glomerulonephritis? |
| Q85397945 | [Update on granulomatosis with polyangitis (GPA, Wegener's granulomatosis)] |
| Q93111593 | [What are the indications for rescue procedures? : Systemic rheumatic diseases in the intensive care unit] |
Search more.